| Literature DB >> 29066903 |
David Feder1, Miriam Eva Koch1, Beniamino Palmieri2, Fernando Luiz Affonso Fonseca1, Alzira Alves de Siqueira Carvalho3.
Abstract
Duchenne muscular dystrophy is the most frequent lethal genetic disease. Several clinical trials have established both the beneficial effect of steroids in Duchenne muscular dystrophy and the well-known risk of side effects associated with their daily use. For many years it has been known that steroids associated with ambulation loss lead to obesity and also damage the bone structure resulting in the bone density reduction and increased incidence of bone fractures and fat embolism syndrome, an underdiagnosed complication after fractures. Fat embolism syndrome is characterized by consciousness disturbance, respiratory failure and skin rashes. The use of steroids in Duchenne muscular dystrophy may result in vertebral fractures, even without previous trauma. Approximately 25% of patients with Duchenne muscular dystrophy have a long bone fracture, and 1% to 22% of fractures have a chance to develop fat embolism syndrome. As the patients with Duchenne muscular dystrophy have progressive cardiac and respiratory muscle dysfunction, the fat embolism may be unnoticed clinically and may result in increased risk of death and major complications. Different treatments and prevention measures of fat embolism have been proposed; however, so far, there is no efficient therapy. The prevention, early diagnosis and adequate symptomatic treatment are of paramount importance. The fat embolism syndrome should always be considered in patients with Duchenne muscular dystrophy presenting with fractures, or an unexplained and sudden worsening of respiratory and cardiac symptoms.Entities:
Keywords: Duchenne muscular dystrophy; fat embolism syndrome; fractures
Year: 2017 PMID: 29066903 PMCID: PMC5644602 DOI: 10.2147/TCRM.S143317
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Figure 1Literature flowchart.
Databases and different keywords
| Keywords | PubMed | Lilacs | Science Direct | Wiley Online | HighWire |
|---|---|---|---|---|---|
| Duchenne muscular dystrophy × fat embolism | 4 | 3 | 1 | 1 | 4 |
| Duchenne dystrophy × fracture | 2 | 31 | 31 | 12 | 21 |
| Fracture × fat embolism | 1 | 9 | 20 | 0 | 0 |
Clinical data from five different reports: FES × DMD
| Study | N | Age (years) | Use of steroids | Non-ambulant | FES, major criteria ≥2 | FES, minor criteria ≥1 | Evolution death |
|---|---|---|---|---|---|---|---|
| Pender et al | 1 | 12 | No | Y | Y, 1 | Y, 1 | 0 |
| Amador et al | 1 | 14 | Y, 1 | Y, 1 | Y, 1 | Y, 1 | 0 |
| Medeiros et al | 8 | 14–13 | Y, 7 | Y, 7 | Y, 8 | Y, 8 | 3 |
| McAdam et al | 5 | 14–23 | Y, 4 | Y, 5 | Y, 5 | Y, 5 | 4 |
| Stein et al | 1 | 15 | Y, 1 | Y, 1 | Y, 1 | Y, 1 | 0 |
Note: Y, present; No, absent.
Abbreviations: DMD, Duchenne muscular dystrophy; FES, fat embolism syndrome.